Homocysteine and methionine metabolism in ESRD: A stable mens. Folic acid-containing regimens have been shown isotope study.
curs in only a small proportion of patients, an observation
The cause of hyperhomocysteinemia in renal failure is unknown, and therapies have not been able to normalize plasma that is currently unexplained. To develop more effective homocysteine levels. Insight into methionine-homocysteine therapies, further insight into the pathogenic mechanism metabolism in ESRD is therefore necessary.
of hyperhomocysteinemia in renal failure is essential.
Methods. Using a primed, continuous infusion of [ 2 H 3 -
Homocysteine is the transmethylation product of the methyl-1- 13 C]methionine, we measured whole body rates of essential sulfur-containing amino acid methionine [10] . methionine and homocysteine metabolism in the fasting state in four hyperhomocysteinemic hemodialysis patients and six S-adenosylmethionine (AdoMet) and S-adenosylhomohealthy control subjects.
cysteine (AdoHcy) are intermediates in this pathway.
Results. Remethylation of homocysteine was significantly
Homocysteine can be either remethylated to methionine decreased in the hemodialysis patients: 2.6 Ϯ 0.2 (sem) vs. 3.8 Ϯ or degraded through the transsulfuration pathway. There 0.3 mol · kg Ϫ1 · hr Ϫ1 in the control subjects (P ϭ 0.03), whereas are two different remethylation pathways. The first retranssulfuration was not 2.5 Ϯ 0.3 vs. 3.0 Ϯ 0.1 mol · kg Ϫ1 · hr Ϫ1 (P ϭ 0.11). The transmethylation rate was proportionally quires 5-methyltetrahydrofolate as methyl donor and reand significantly lower in the ESRD patients as compared with duced cobalamin as a cofactor. 5-Methyltetrahydrofolate controls: 5.2 Ϯ 0.4 vs. 6.8 Ϯ 0.3 mol · kg Ϫ1 · hr Ϫ1 (P ϭ 0.02).
is generated by a reaction catalyzed by 5,10-methyleneMethionine fluxes to and from body protein were similar.
tetrahydrofolate reductase (MTHFR), of which a com-
Conclusions.
The conversion of homocysteine to methiomon, thermolabile, and less active variant resulting from nine is substantially (approximately 30%) decreased in hemodialysis patients, whereas transsulfuration is not. Decreased a cytidine to thymidine point mutation at position 677 has remethylation may explain hyperhomocysteinemia in ESRD.
been described [11] . The second remethylation reaction cystathionine, which is subsequently cleaved into cysteine and ␣-ketobutyrate. Both reactions are irreversible and require the active form of vitamin B 6 , pyridoxal Hyperhomocysteinemia is an independent cardiovas-5Ј-phosphate, as a cofactor. cular risk factor in end-stage renal disease (ESRD) [1] Possible pathophysiological mechanisms of hyperhowith a prevalence as high as 85 to 100% [2, 3] . Many mocysteinemia in renal failure focus on a decreased dialysis patients are therefore at risk, necessitating the homocysteine metabolism in or outside of the kidney. development and testing of adequate treatment regiPatients with chronic renal failure exhibit a substantial decrease in plasma homocysteine clearance after oral homocysteine loading [12] . The loss of urinary homocys- there is a net uptake of homocysteine in the normal rat described by Storch et al [18] . Because of the presence of four additional neutrons, this stable isotope has a kidney [16] . However, we have recently shown that the kidney does not extract homocysteine from the circulamolecular weight of m ϩ 4 relative to natural methionine (m). The metabolism of methionine and homocysteine tion in fasting humans with normal renal function [17] .
To understand the pathophysiology of hyperhomocysoccurs in the intracellular compartment. We assumed that the intracellular and intravascular compartments are teinemia in ESRD, it is necessary to quantitatively assess methionine transmethylation and homocysteine remethin rapid and complete isotopic equilibrium. In steadyylation and transsulfuration in ESRD patients. In this state conditions, the appearance and disappearance of study, we used a stable isotope tracer technique to deterwhole body methionine can be determined [18, 19] . mine whole body rates of use of methionine and homoMethionine is the only known precursor of homocysteine cysteine in ESRD patients and in healthy control subin humans, and when no dietary intake of methionine jects.
takes place, remethylation of homocysteine and endogenous protein breakdown are the only sources of methionine. Table 1. breath air after passage through the body bicarbonate The study protocol was approved by the ethics compool. The m ϩ 4 methionine tracer is diluted by methiomittee of the University Hospital Vrije Universiteit, and nine entering the pool via the diet, from homocysteine all participants gave their written informed consent.
remethylation, and by free methionine entering from protein breakdown in the tissues. In steady state, the Experimental design rate of appearance of methionine from these sources equals the rate of disappearance (that is, protein syntheWe used doubly labeled methionine (L-[ 2 H 3 -methyl-1- 13 C]methionine) as a tracer, according to the method sis and transmethylation).
Yorba Linda, CA, USA). Internal calibration for carbon dioxide and volume were conducted before each infusion. Gas volumes were automatically corrected for temperature and air pressure. C]methionine was given followed by a continuous infusion for six hours. In five control subjects,
Tracer administration
minutes. Both solutions were tested for pyrogens. At tracer infusion was discontinued after five hours as plateau was reached t ϭ 0, priming doses were given of 13 C-bicarbonate (5.9
after 220 minutes. Blood and breath samples were taken as indicated.
mol) and L-[ 2 H 3 -methyl-1-13 C]methionine (2.9 mol · After 120 minutes, indirect calorimetry was performed.
kg Ϫ1 in the control subjects, and 3.5 mol · kg Ϫ1 in the dialysis patients, in order to adjust for their larger homocysteine pool size). Thereafter, a six-hour continuous Infusion protocol infusion of L-[ 2 H 3 -methyl-1-
13
C]methionine (1.8 and 2.2 mol · kg Ϫ1 · hr Ϫ1 in controls and ESRD patients, All subjects were kept on a fixed diet containing 1.0 g protein/kg body weight/day for three days prior to the respectively) was conducted with a calibrated precision infusion pump (Teruma, Tokyo, Japan). After having study. The experiments were conducted after an overnight fast. Fasting was continued throughout the infusion assessed in the first control subject that plateau enrichments were already obtained after 220 minutes, the infuperiod. Only small amounts of tap water given orally were allowed. The hemodialysis patients were studied sion period was shortened to five hours in the remaining five healthy subjects. Plateau enrichments levels were one day prior to a regular midweek dialysis session. All subjects were kept in bed during the study period. At calculated as the mean of the final five 20-minute interval samples of the infusion period. 8:00 a.m., two intravenous catheters were placed in a dorsal hand vein, one for infusion of substances and Laboratory analyses one in the contralateral hand for sampling. Arterialized blood samples were drawn from the dorsal hand vein For isotopic analysis of methionine, the acetyl-3,5 bis,-trifluoromethylbenzyl derivative was prepared from 500 after the hand was inserted in a heated hand box [20] . In the hemodialysis patients, blood samples were drawn l plasma samples. Samples were purified with anionexchange chromatography according to Stabler et al [21] . from the arterial end of the arteriovenous fistula. Blood was collected in heparinized glass tubes, immediately
The dried elutes were derivatized with acetic anhydride (50 l in 1 ml 1 m phosphate buffer, 40ЊC) and 3,5 bis,-placed on ice, and centrifuged for 10 minutes at 3000 r.p.m. at Ϫ4ЊC within 15 minutes. Plasma was stored trifluoromethylbenzylbromide (10% in acetonitrile). The enrichments of [1-13 C]methionine and [ 2 H 3 -methylat Ϫ30ЊC until analyzed. Samples of end-tidal-expired breath air were collected in a 15 ml Venoject tube by 1-13 C]methionine were measured by gas chromatography mass spectrometry (GCMS) with negative ion chemical instructing the subjects to exhale through a straw. During the last three seconds of expiration, the straw was withionization (with NH 3 ) on a Hewlett-Packard (Palo Alto, CA, USA) 5989B quadruple GCMS machine. Selected drawn from the tube, which was immediately closed by the investigator.
monitoring was set to Ϫm/z ϭ 190, 191, and 194 for the acetyl-bis,trifluoromethylbenzylbromide derivative of Before each infusion, three baseline blood and breath samples were collected for the determination of natural tracee (m) and tracer isotopomers ([1-
C]methionine, m ϩ 1, and [ 2 H 3 -methyl-1- 13 C]methionine, m ϩ 4), reabundances of methionine isotopes and 13 CO 2 , respectively. During the infusion, blood and breath samples spectively. Enrichments (in MPE) were calculated on the basis of the abundance relative to all measured methiwere taken at regular intervals (Fig. 1) . After completion of the protocol, the intravascular catheters were withonine species: m ϩ 0, m ϩ 1, and m ϩ 4 [18, 22] . Calibration curves obtained by measurement of standard mixdrawn, and the subjects were allowed to eat.
Carbon dioxide production was measured during 30 tures containing weighed amounts of tracer and tracee were used to correct for minor instrument variation. minutes with a ventilated hood using an indirect calorimeter (2900 Metabolic Measurement Cart; SensorMedics, The (N ϭ 3) . The geometric mean of the three baseline breath where I d is the tracee methionine intake via the diet (in air 13 CO 2 values was subtracted from each sample to this study, I d equals zero as subjects were fasting). B establish a 13 CO 2 enrichment as AP excess (APE). is methionine release from protein breakdown. RM is At baseline, plasma total (that is, free and protein homocysteine remethylation. S is methionine incorporabound) homocysteine was measured by high-perfortion in protein synthesis. TM is methionine transmethylamance liquid chromatography (HPLC) with fluorescence tion, and TS is the transsulfuration rate. Transsulfuration detection according to the method of Ubbink, Vermaak is calculated from the 13 CO 2 excretion in breath air as and Bissbort [23] . Baseline serum folate and vitamin B 12 follows: levels were determined by radioassay (ICN Pharmaceuticals, Costa Mesa, CA, USA) and serum pyridoxal phos-TS ϭ V 13 CO 2 * (1/[ 13 C] methionine enrichment phate by fluorescence HPLC. The methionine concentrain plasma Ϫ 1/[ 13 C] methionine tion in the infusate was measured in each experiment enrichment in tracer infusate) (Eq. 5) using a standard amino acid analyzer equipped with a in which V 13 CO 2 equals carbon dioxide production (in high-pressure analytical column packed with Utrapac 8 mol · hr Ϫ1 ) * breath air 13 CO 2 enrichment (in APE/100) resin [Biochrom 20; Pharmacia Biotech (Biochrom Ltd.), * bicarbonate retention factor (assumed to be 0.72) [24] . Cambridge, UK].
As the 13 C in the carboxyl moiety is not removed durThe MTHFR C677T polymorphism was assessed in ing transmethylation and remethylation, equations 3 and DNA obtained from the buffy coat of ethylenediamine-4 can be rearranged into: tetraacetic acid (EDTA) blood. The polymerase chain reaction conditions and the sequence of the primers used RM ϭ Q m Ϫ Q c (Eq. 6) in the amplification of the part of the gene containing As methionine is the only precursor of homocysteine, the mutation were taken from Frosst et al [11] . HinfI the homocysteine disappearance (RM ϩ TS) equals restriction enzyme analysis of the polymerase chain reachomocysteine appearance (TM); thus: tion products and subsequent electrophoresis in a 3% agarose gel were used to determine the mutation status TM ϭ RM ϩ TS (Eq. 7) of the subject.
Methionine regression was performed in the total group after adding Q m ϭ I * (E tr /E 4 Ϫ 1) (Eq. 1) a factor "ESRD present (0) or absent (1)" to the model. A P value Ͻ 0.05 was accepted as the level of significance. Q c ϭ I * (E tr /(E 1 ϩ E 4 ) Ϫ 1) (Eq. 2)
where I is the tracer infusion rate (in mol · hr
Ϫ1
), E tr RESULTS the enrichment of the tracer in the infusate (m ϩ 4, 95 MPE), and E 1 and E 4 are the plasma plateau enrichments Plateau plasma methionine and breath air 13 CO 2 enrichments were obtained in all individuals (analysis of of [1- 13 C]methionine (m ϩ 1) and [ 2 H 3 -methyl-1- 13 C]methionine (m ϩ 4), respectively. variance, P Ͻ 0.05) with a mean of coefficient of variation of 7% (N ϭ 5 samples). In the ESRD patients, the plaIn the steady state, the sum of inputs equals the sum of outputs for various components, as described earlier teau was reached after 260 minutes and, in the control Abbreviations are: Q m , methionine methylflux; Q c , methionine carboxylflux; RM, remethylation; TS, transsulfuration; TM, transmethylation; B, methionine from protein breakdown; S, methionine to protein synthesis. subjects, after 220 minutes. Conditions for mass spectrometry measurements were similar in both groups (isotopic enrichment ranged between 1 to 2 MPE for [1- C]methionine, and breath air 13 CO 2 was Ͼ0.0020 APE in each subject). The carbon dioxide production was similar in patients and controls (ESRD, 2.60 Ϯ 0.33; controls, 2.61 Ϯ 0.09 ml · kg Ϫ1 · min Ϫ1 , P ϭ 0.97).
Results for conversion rates in the methionine-homocysteine cycle calculated from the tracer study are presented in Table 2 . Remethylation and transmethylation were both significantly decreased in the ESRD group, whereas transsulfuration, protein synthesis, and breakdown were not significantly different. Figure 2 depicts the individual results for remethylation and transmethylation in both groups. Remethylation and transmethylation rates were highly correlated when data from both groups were pooled (r ϭ 0.95, P Ͻ 0.001). The transsulfuration rate also showed a significant correlation with transmethylation (r ϭ 0.74, P ϭ 0.01), but no significant correlation with remethylation. Hyperhomocysteinemia was present in all ESRD pais given for the total group. Symbols are: (ᮀ) control subjects; (᭹) tients, whereas the control subjects had plasma total hemodialysis patients.
homocysteine levels within the reference range (that is, Յ15 mol/liter). Serum folate, vitamin B 12 and vitamin B 6 levels were similar in both groups. None of the dialysis DISCUSSION patients were homozygous for the MTHFR C677→T mutation. Multivariate analysis showed that lower re-
The results of this investigation are the first data on in vivo rates of methionine and homocysteine metabomethylation and transmethylation were significantly related to being an ESRD patient (standardized r ϭ 0.68, lism in patients with renal disease. At increased concentrations of total homocysteine in plasma of these pa-P ϭ 0.03, and standardized r ϭ 0.72, P ϭ 0.02, respectively), but not to any of the B vitamins, sex, or age.
tients, the homocysteine transsulfuration appeared not to be affected when compared with apparently healthy The only significant determinant of transsulfuration was serum vitamin B 6 (standardized r ϭ 0.64, P ϭ 0.045).
control subjects. In contrast, the methionine transmeth-ylation and the homocysteine remethylation were prosteady-state conditions. Guttormsen et al studied bioavailability and distribution volume by oral and intraveportionally decreased. In the healthy control subjects, the calculated postabsorptive rates of homocysteine renous homocysteine (and not methionine) loading [12] . They found that folic acid therapy did not normalize methylation, homocysteine transsulfuration, and methionine transmethylation were virtually identical to those total body homocysteine clearance after homocysteine loading. These findings do not necessarily contradict our reported by the group of Young et al applying the same isotope model and at similar dietary nitrogen intake of data. In addition to an impaired homocysteine remethylation, which is best detected in the fasting steady state, 1.0 g · kg Ϫ1 · day Ϫ1 [25] . In patients with ESRD, only a nonsignificant trend renal failure patients may have a transsulfuration defect on homocysteine or methionine loading as well. Such a was observed toward lower rates of homocysteine transsulfuration compared with healthy control subjects. A defect is not likely to be responsive to folate therapy. On theoretical grounds, elevated fasting transmethylacloser analysis of the data in Table 2 shows that this trend is mainly due to the very low rate of homocysteine tion could be postulated as a cause of hyperhomocysteinemia. When fasting transsulfuration is unchanged, transsulfuration measured in patient 1. This patient also had the lowest vitamin B 6 concentration (11 nmol · l Ϫ1 ). remethylation would be elevated as well as a consequence. Our observations point to the opposite. TransBecause in the whole group of subjects serum vitamin B 6 was found to be a determinant of homocysteine transmethylation is decreased, which is a counter-intuitive finding as less supply is an unlikely explanation for elesulfuration in the multivariate analysis, the tendency toward a lower rate of homocysteine transsulfuration in vated plasma homocysteine levels. However, remethylation is also decreased and evidently more impaired than the ESRD patients may be related to their tendency of having a lower serum vitamin B 6 concentration. In that the consequential decrease in transmethylation. Several factors may be implicated in the decreased case, it can be concluded that ESRD per se does not affect the homocysteine transsulfuration. Irrespective of homocysteine remethylation in ESRD. The most obvious cause is a low folate and/or vitamin B 12 status, but the level of total homocysteine in plasma in patients with ESRD, a significant and proportional decrease in the this was not the case in our patients. Alternative disturbances in folate metabolism that have been described methionine transmethylation and homocysteine remethylation was observed. A remarkable finding was that the in ESRD patients include an impaired transmembrane transport of folic acid [26] and a decreased activity of patient with polycystic kidney disease had the lowest remethylation and also the lowest plasma homocysteine, plasma folate conjugase, an enzyme that splits polyglutamate forms of folate into biologically more active oligowhich could indicate that patients with polycystic kidney disease constitute a different patient population. This glutamates and monoglutamates [27] . Further evidence for a disturbed folate metabolism is provided by interissue requires further investigation. Nevertheless, the results of this study indicate that an impaired whole body vention studies that show that only folic acid-containing regimens are able to lower, but not normalize, plasma remethylation of homocysteine, and not its transsulfuration, is a plausible cause of hyperhomocysteinemia in homocysteine levels in renal failure patients [3] [4] [5] [6] [7] [8] [9] . It remains to be elucidated whether the homocysteine rehemodialysis patients. This may seem a somewhat unexpected finding, particularly in view of the data of Guttormethylation rate in ESRD patients remains decreased during folic acid treatment. In addition, it can not be msen et al [12] . They observed a significantly decreased clearance of total homocysteine from plasma in patients excluded that the concentration or the activity of the enzymes involved in homocysteine remethylation are alwith chronic renal failure. The decreased clearance could not be influenced by the administration of folic acid. tered in ESRD. Homozygosity for the thermolabile MTHFR variant has a similar frequency of approxiThey concluded that the decreased clearance in patients with renal failure could not be due a defect in homocysmately 10 to 15% in ESRD patients and in control subjects [28, 29] , which makes this enzyme a priori an unteine remethylation and speculated that the decreased clearance of total homocysteine was brought about by likely candidate to explain the 85 to 100% prevalence of hyperhomocysteinemia in ESRD. As none of the dialysis decreased renal extraction of homocysteine. This speculation was based on findings in postabsorptive rats, showpatients in our study were homozygous for the C677→T mutation, the decreased homocysteine remethylation ing net renal extraction an subsequent renal transsulfuration of homocysteine [15, 16] . We have, however, could evidently not be explained by the thermolabile MTHFR enzyme variant. Also, abnormalities in the berecently shown that such a mechanism is not of importance in humans, because no net renal extraction of taine-dependent remethylation pathway do not offer a plausible explanation, as betaine, when added to folic homocysteine was observed in fasting humans [17] . It should be stressed that the findings in this study are true acid, does not further lower plasma homocysteine in hemodialysis patients [3] . Finally, regulatory factors in under the assumption that body compartments are in complete equilibrium and that they pertain to fasting methionine-homocysteine metabolism may be altered in
